🇺🇸 FDA
Pipeline program

Venetoclax

IIT2024055

Phase 2 small_molecule active

Quick answer

Venetoclax for FLT3 Gene Mutation is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
FLT3 Gene Mutation
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials